

- ◆ **Active epilepsy:** two or more unprovoked epileptic seizures on different days in the prior year that are disabling to the individual.
- ◆ **Annual health reporting system:** the preparation of yearly reports covering health service functions, including the use of allocated funds.
- ◆ **Awareness and advocacy:** a combination of individual and social actions designed to raise awareness and gain political commitment, policy support, social acceptance and health systems support for people with epilepsy.
- ◆ **Budget:** a separate regular source of money, available in a country's health budget allocated for actions directed towards epilepsy care in the country.
- ◆ **Aetiology of epilepsy:** the underlying abnormality of the brain, as epileptic seizures are nonspecific responses of the brain to all kinds of insult.
- ◆ **Daily defined dose (DDD):** the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDDs were obtained from the WHO Collaborating Centre for Drug Statistics Methodology (<http://www.whocc.no/atcddd/>).
- ◆ **Disability benefits:** benefits payable as a part of legal right from public funds in cases of epilepsy that cause physical, mental or intellectual impairment leading to functional limitations.
- ◆ **Education:** improving the knowledge of patients and society about epilepsy and its consequences and their understanding of psychosocial and occupational problems, so as to encourage them to cope actively with the disorder and live with as few limitations as possible.
- ◆ **Epidemiological or service data collection system:** an organized information-gathering system for service activity data for epilepsy; usually incorporates incidence and prevalence rates of diseases, admission and discharge rates, numbers of outpatient and community contacts and other activities.
- ◆ **Epilepsy specialists:** persons in the health sector devoted to providing epilepsy care.
- ◆ **Epilepsy surgery:** any neurosurgical intervention with the primary goal of relieving intractable epilepsy.
- ◆ **Epileptic seizure:** transient occurrence of signs or symptoms caused by abnormal excessive or synchronous neuronal activity in the brain.
- ◆ **Essential drug list:** the officially approved list of essential drugs that a country has implemented; usually adapted from the WHO Model List of Essential Drugs.
- ◆ **Government policy of licensing of antiepileptic drugs:** authorization by the government of antiepileptic drugs that are either purchasable over the counter or necessitate a prescription from a general practitioner or a specialist.
- ◆ **Hospital bed for epilepsy care:** a hospital bed maintained only for use by patients with epilepsy as a primary diagnosis on a continuous basis. These beds may be for short-term use for diagnostic purposes or for residential long-term care; usually they are located in neurological services or hospitals or special epilepsy centres.
- ◆ **International dollar:** a hypothetical currency that is used as a means of translating and comparing costs from one country to another using a common reference point, the US dollar. An international dollar has the purchasing power of the US dollar in the United States. To convert international dollars to local currency units, multiply the international dollar figure by the purchasing power parity (PPP, see below) exchange rate. For example, 2 international dollars are equal to 24.102 Thai bhat for the year 2000 ( $2 \times 12.051$ ). To convert local currency units to international dollars, divide the local currency unit by the PPP exchange rate.
- ◆ **Lay organizations:** voluntary organizations, charitable groups, service user or advocacy groups working in the area of epilepsy.
- ◆ **Long-term video/EEG monitoring:** the continuous recording of electroencephalography (EEG) patterns for hours, days or weeks combined with continuous recording of audio and video signals from a closed-circuit television system for the analysis of seizure semiology.
- ◆ **Neurological nurse:** a registered nurse who has successfully completed the required additional training in neurological nursing.
- ◆ **Neurologist:** a medical graduate who has successfully completed at least two years of postgraduate training in neurology.
- ◆ **Neuropaediatrician:** a specialist (neurologist or paediatrician) with at least one year of recognized sub-specialist training in child neurology.
- ◆ **Neuropsychological services:** facilities where the evaluation and assessment of cognitive strengths and weaknesses are carried out.
- ◆ **Neurosurgeon:** a medical graduate who has successfully completed at least two years of postgraduate training in neurosurgery.
- ◆ **Out-of-pocket payments:** payments made for epilepsy care by patients or their families.

- ◆ **Prevalence of epilepsy:** proportion of people with epilepsy in a given population at a specified time (point prevalence) or during a defined time interval (period prevalence).
- ◆ **Prevention:** all organized activities in the community to prevent occurrence as well as progression of epilepsy and to minimize the psychosocial consequences.
- ◆ **Primary care:** the provision of basic preventive and curative health care to people with epilepsy at the first point of entry into the health system.
- ◆ **Private foundations:** privately owned institutions that provide funding or financial support for epilepsy care and epilepsy services in the country.
- ◆ **Private insurance:** voluntary payment of a premium by health-care consumers to a private health insurance company which, in return, pays for part or all of their epilepsy care.
- ◆ **Professional organizations:** associations of physicians and other health professionals in the field of patient care, research or education in epilepsy and whose principal concern is with the problems of epilepsy; such associations are usually nongovernmental.
- ◆ **Promotion:** a process of enabling people to increase control over the determinants of their health and well-being and to effect improvement.
- ◆ **Psychiatrist:** a medical doctor who has successfully completed at least two years of postgraduate training in psychiatry.
- ◆ **Psychologist:** a graduate from a university-level school of psychology with specialization in clinical psychology.
- ◆ **Purchasing power parity (PPP) exchange rate:** the number of units of a country's currency required to buy the same amount of goods and services in the domestic market as US\$ 1.00 would buy in the United States. The PPP exchange rates used in this analysis were developed by WHO and are available on the web site <http://www.who.int/evidence/cea>.
- ◆ **Rehabilitation:** care given to patients with epilepsy to help them achieve their optimum level of functioning.
- ◆ **Sheltered work:** protected environments where people with disabilities can experience the stimulation and learning required to work and earn their living, without the pressure that exists in usual settings.
- ◆ **Social insurance:** a fixed percentage of income that everyone generally above a certain level of income is required to pay to a government-administered health insurance fund which, in return, pays for part or all of consumers' epilepsy care.
- ◆ **Social rehabilitation:** services as part of a programme aimed at enhancing social skills, facilitating integration into working life and developing independent living skills.
- ◆ **Social worker:** a graduate from a university-level school of social work.
- ◆ **Special education:** education facilities within specialist settings aimed at children with learning difficulties.
- ◆ **Special equipment:** tools for the rehabilitation of people with epilepsy to allow them a better quality of life, such as seizure alarms, non-suffocating pillows and protective helmets.
- ◆ **Tax-based funding:** money for health services raised by general taxation or through taxes earmarked specifically for epilepsy services; includes health services that are fully financed by government.
- ◆ **Therapeutic drug monitoring:** the use of antiepileptic drug measurements in biological fluids as an aid to the management of patients receiving antiepileptic drug therapy.
- ◆ **Training in epileptology:** specialist training in the diagnosis, treatment, prevention, care, rehabilitation and research in epilepsy, for medical graduates and professionals allied to medicine.
- ◆ **Treatment:** relevant clinical and non-clinical care aimed at reducing the impact of epilepsy and improving the quality of life of people with epilepsy.
- ◆ **Treatment gap:** the difference between the number of people with active epilepsy and the number whose seizures are being appropriately treated in a given population at a given point in time, expressed as a percentage; this definition includes diagnostic and therapeutic deficits.

1. Engel J Jr, Pedley TA, eds. *Epilepsy: a comprehensive textbook. Vols 1, 2 and 3*. Philadelphia, PA, Lippincott-Raven Publishers, 1997.
2. Meinardi H et al. on behalf of the ILAE Commission on the Developing World. The treatment gap in epilepsy: the current situation and ways forward. *Epilepsia*, 2001, 42:136–149.
3. Reynolds EH, ed. Epilepsy in the world. Launch of the Second Phase of the ILAE/IBE/WHO Global Campaign Against Epilepsy. *Epilepsia*, 2002, 43(Suppl.6):1–3.
4. *Atlas of mental health resources in the world*. Geneva, World Health Organization, 2001.
5. *Atlas of country resources for neurological disorders*. Geneva, World Health Organization, 2004.
6. *World Bank list of economies (April 2005)*. Washington, DC, World Bank, 2005 (<http://www.worldbank.org>, accessed April 2005).
7. Kinnier Wilson JV, Reynolds EH. Translation and analysis of a cuneiform text forming part of a Babylonian treatise on epilepsy. *Medical History*, 1990, 34:185–198.
8. Hippocrates. The sacred disease. In: *The genuine works of Hippocrates*. Birmingham, AL, The Classics of Medicine Library, Gryphon Editions, 1985.
9. Temkin O. *The falling sickness*, 2nd ed. Baltimore, MD, Johns Hopkins University Press, 1971.
10. Willis T. Pathology of the brain and nervous stock: on convulsive diseases. In: Pordage S, ed. *The remaining medical works of that famous and renowned physician Dr Thomas Willis of Christ Church in Oxford, and Sidley Professor of Natural Philosophy in that famous University*. London, Dring, Harper, Leigh and Martyn, 1684: 1–89.
11. Todd RB. On the pathology and treatment of convulsive diseases. *London Medical Gazette*, 1849, 8:661–671; 724–729; 766–772; 815–822; 837–846.
12. Jackson JH. On convulsive seizures. *Lancet*, 1890, 1:685–688; 735–738; 785–788.
13. Ferrier D. *The functions of the brain*. London, Smith Elder, 1876.
14. Fritsch GT, Hitzig E. Über die elektrische Erregbarkeit des Grosshirns. *Archiv für Anatomie, Physiologie und Wissenschaftliche Medizin*, 1870, 300–332.
15. Herpin T. *Du pronostic et du traitement curatif de l'épilepsie [Prognosis and curative treatment of epilepsy]*. Paris, 1852.
16. Jackson JH. On the anatomical, physiological and pathological investigation of epilepsies. *West Riding Lunatic Asylum Medical Reports*, 1873, 3:315–339.
17. Gowers WR. *Epilepsy and other chronic convulsive disorders*. London, J & A Churchill, 1881.
18. Caton R. Interim report on investigation of the electric currents of the brain. *British Medical Journal*, 1877; 1(suppl.):62–65.
19. Berger H. Über das Elektrenkephalogramm des Menschen. *Archiv für Psychiatrie und Nervenkrankheiten*, 1929, 87:527–570.
20. Reynolds EH. The John Hughlings Jackson 1935 Centenary Congress Medal. *Journal of neurology, neurosurgery, and psychiatry*, 2005, 76 (in press).
21. Hodgkin AL, Huxley AF. A quantitative description of membrane current and its application to conduction and excitation in nerve. *The Journal of Physiology*, 1952, 117:500–544.
22. Reynolds EH. Todd, Faraday and the electrical basis of epilepsy. *Epilepsia*, 2004, 45:985–992.
23. Taylor DC. One hundred years of epilepsy surgery: Sir Victor Horsley's contribution. *Journal of neurology, neurosurgery, and psychiatry*, 1986, 49:485–488.
24. Meinardi H. International League Against Epilepsy and its journal *Epilepsia* 1909–1999. Hilversum, Van der Weij BV Grafische Bedrijven, 1999.
25. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. *Epilepsia*, 1981, 22:489–501.
26. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. *Epilepsia*, 1989, 30:389–399.
27. Reynolds EH. ILAE/IBE/WHO Global Campaign “Out of the Shadows”: global and regional developments. *Epilepsia*, 2001, 42:1094–1100.
28. Schoenberg BS. Epidemiologic aspects of epilepsy. In: Nistico G et al., eds. *Epilepsy: an update on research and therapy*. New York, Alan R. Liss Inc., 1983:331–343.
29. Bharucha NE, Shorvon SD. Epidemiology in developing countries. In: Engel J Jr, Pedley TA, eds. *Epilepsy – a comprehensive textbook*. Philadelphia, PA, Lippincott-Raven Publishers, 1997:105–118.
30. Smith D, Defalla BA, Chadwick DW. The misdiagnosis of epilepsy and the management of refractory epilepsy in a specialist clinic. *Quarterly Journal of Medicine*, 1999, 92:15–23.
31. Commission of Epidemiology and Prognosis. Guidelines for epidemiological studies on epilepsy. *Epilepsia*, 1993, 34:592–596.
32. Hauser AW, Hesdorffer DC. *Epilepsy: frequency, causes and consequences*. New York, Demos Publications, 1990.
33. Jallon P. Epilepsy and epileptic disorders, an epidemiological study. *Epileptic Disorders*, 2002, 4:1–12.
34. ILAE Commission Report. The epidemiology of the epilepsies: future directions. *Epilepsia*, 1997, 38:614–618.
35. Preux PM, Druet-Cabanac M. Epidemiology and aetiology of epilepsy in sub-Saharan Africa. *Lancet Neurology*, 2005, 4:21–31.

36. Hauser WA. Should people be treated after a first seizure? In: Engel J Jr, Pedley TA, eds. *Epilepsy – a comprehensive textbook*. Philadelphia, PA, Lippincott-Raven Publishers, 1997: 47–57.
37. Berg AT et al. Newly diagnosed epilepsy in children: presentation at diagnosis. *Epilepsia*, 1999, 40:445–452.
38. Berkovic SF, Scheffer IE. Genetics of the epilepsies. *Epilepsia*, 2001, 42(Suppl5):16–23.
39. Berg AT, Shinnar S. The risk of seizure recurrence following a first unprovoked seizure: a quantitative review. *Neurology*, 1991, 41:965–972.
40. Hauser WA et al. Risk of recurrent seizures after two unprovoked seizures. *New England Journal of Medicine*, 1998, 338:429–434.
41. Kwan P, Brodie MJ. Early Identification of refractory epilepsy. *New England Journal of Medicine*, 2000; 343:314–319.
42. Gaitatzis A, Sander JW. The mortality of epilepsy revisited. *Epileptic Disorders*, 2004, 6:3–13.
43. Gaitatzis A et al. The epidemiology of the comorbidity of epilepsy in the general population. *Epilepsia*, 2004, 45:1613–1622.
44. Pal DK et al. Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. *Lancet*, 1998, 351:19–23.
45. Johnson MR, Sander JW. The clinical impact of epilepsy genetics. *Journal of neurology, neurosurgery, and psychiatry*, 2001, 70:428–430.
46. Hesdorffer DC, Verity CM. Risk factors. In: Engel J Jr, Pedley TA, eds. *Epilepsy: a comprehensive textbook*. Philadelphia, PA, Lippincott-Raven Publishers, 1997:59–68.
47. Sander JW et al. National General Practice Study of Epilepsy: newly diagnosed epileptic seizures in a general population. *Lancet*, 1990, 336:1267–1271.
48. Kwan P, Sander JW. The natural history of epilepsy: an epidemiological view. *Journal of neurology, neurosurgery, and psychiatry*, 2004; 75(10):1376–1381.
49. Sander JW, Shorvon SD. Epidemiology of the epilepsies. *Journal of neurology, neurosurgery, and psychiatry*, 1996, 61:433–443.
50. Lhatoo S, Sander JW. The epilepsies. In: Brandt T et al., eds. *Neurological disorders: course and treatment*. San Diego, CA, Academic Press, 2003:207–234.
51. Annegers JF, Rocca WA, Hauser WA. Causes of epilepsy: contributions of the Rochester epidemiology project. *Mayo Clinic Proceedings*, 1996, 71:570–575.
52. Sander JW. Infectious agents and epilepsy. In: Knobler S et al., eds. *The infectious aetiology of chronic diseases: defining the relationship, enhancing the research and mitigating the effects*. Washington, DC, The National Academies Press, 2004:93–99.
53. Kwan P, Brodie MJ. Refractory epilepsy: a progressive, intractable but preventable condition? *Seizure*, 2002, 11:77–84.
54. Brodie MJ et al. Commission on European Affairs: appropriate standards of epilepsy care across Europe. *Epilepsia*, 1997, 38:1245–1250.
55. Malmgren K et al. The provision of epilepsy care across Europe. *Epilepsia*, 2003, 44:727–731.
56. Kwan P, Brodie MJ. Phenobarbital for the treatment of epilepsy in the 21st century: a critical review. *Epilepsia*, 2004, 45:1141–1149.
57. Brodie MJ, Kwan P. The star systems: overview and use in determining antiepileptic drug choice. *CNS Drugs*, 2001, 18:1–12.
58. Brodie MJ, Kwan P. Staged approach to epilepsy management. *Neurology*, 2002, (Suppl 5):S2–S8.
59. Specchio LM, Beghi E. Should antiepileptic drugs be withdrawn in seizure-free patients? *CNS Drugs*, 2004, 18:201–212.
60. Schachter SC. Vagus nerve stimulation therapy summary. Five years after FDA approval. *Neurology*, 2002, 59 (Suppl 4): S15–S20.
61. Kossof EH. More fat and fewer seizures: dietary therapies for epilepsy. *Lancet Neurology*, 2004, 3:415–420.
62. Scottish Intercollegiate Guidelines Network (SIGN) 70. *Diagnosis and management of epilepsy in adults*. place, SIGN, 2003 (<http://www.sign.ac.uk>).
63. Mani KS et al. Epilepsy control with phenobarbital or phenytoin in rural south India: the Yelandur Study. *Lancet*, 2001, 357:1316–1320.
64. Nimaga K et al. Treatment with phenobarbital and monitoring of epileptic patients in rural Mali. *Bulletin of the World Health Organization*, 2002, 80:532–537.
65. Trevathan E, Gilliam F. Lost years delayed referral for surgically treatable epilepsy. *Neurology*, 2003, 61:432–433.
66. Jallon P. Epilepsy in developing countries. *Epilepsia*, 1997, 38:1143–1151.
67. Osuntokun BO. Epilepsy in Africa: epidemiology of epilepsy in developing countries in Africa. *Tropical and Geographical Medicine*, 1978, 30:23–32.
68. Global Campaign Against Epilepsy. *Epilepsy in the WHO African Region: bridging the gap*. Brazzaville, World Health Organization Regional Office for Africa, 2004 (AFR/MNH/04.1).
69. Watts AE. The natural history of untreated epilepsy in a rural community in Africa. *Epilepsia*, 1992, 33:464–468.
70. Reis R. 1994. Evil in the body, disorder of the brain. Interpretations of epilepsy and the treatment gap in Swaziland. *Tropical and Geographical Medicine*, 1994, 46(Suppl): S406–S443.

71. Shorvon SD, Farmer PJ. Epilepsy in developing countries: a review of epidemiological, sociocultural, and treatment aspects. *Epilepsia*, 1988, 29(Suppl):S36–S54.
72. Diop AG et al. Filières des soins anti-épileptiques en Afrique [Channels of epilepsy care in Africa]. *Epilepsie*, 1998, 10:115–121.
73. Danesi MA, Adetunji JB. Use of alternative medicine by patients with epilepsy: a survey of 265 epilepsy patients in a developing country. *Epilepsia*, 1994, 35:344–351.
74. Bertolote JM. Epilepsy as a public health problem: the role of the World Health Organization and of cooperation between WHO and nongovernmental organizations. *Tropical and Geographical Medicine*, 1994, 46(Suppl):S28–S30.
75. Nimaga K et al. Treatment with phenobarbital and monitoring of epileptic patients in rural Mali. *Bulletin of the World Health Organization*, 2002, 80:532–537.
76. Engel J Jr. Surgery for seizures. *New England Journal of Medicine*, 1996, 334:647–652.
77. Diop AG et al. The Global Campaign against Epilepsy in Africa. *Acta Tropica*, 2003, 87:149–159.
78. Engel J Jr. Historical perspectives. In: Engel J Jr, ed. *Surgical treatment of the epilepsies*, 2nd ed. New York, NY, Raven Press, 1993, 695–705.
79. Horsley V. Brain surgery. *British Medical Journal*, 1886, 2:670–675.
80. Bailey P, Gibbs FA. The surgical treatment of psychomotor epilepsy. *Journal of the American Medical Association*, 1951, 145:365–370.
81. Jasper H, Pertuiset B, Flanigin H. EEG and cortical electrograms in patients with temporal lobe seizures. *Archives of Neurology and Psychiatry*, 1951, 65:272–290.
82. Engel J Jr, ed. *Surgical treatment of the epilepsies*, 2nd ed. New York, NY, Raven Press, 1993.
83. Lüders HO, Comair YG. *Epilepsy surgery*, 2nd ed. Philadelphia, PA, Lippincott Williams & Wilkins, 2001.
84. Engel J Jr. Current concepts: surgery for seizures. *New England Journal of Medicine*, 1996, 334:647–652.
85. Engel J Jr et al. Practice parameter: temporal lobe and localized neocortical resections for epilepsy. *Neurology*, 2003, 60:538–547.
86. Wiebe S et al. A randomized, controlled trial of surgery for temporal lobe epilepsy. *New England Journal of Medicine*, 2001, 345:311–318.
87. Mathern GW, ed. Pediatric epilepsy and epilepsy surgery. *Developmental Neuroscience*, 1999, 21:163–406.
88. Wieser H-G, Silfvenius H, ed. Epilepsy surgery in developing countries. *Epilepsia*, 2000, 41(Suppl 4):1–50.
89. Engel J Jr et al. Alternative treatments. In: *Epilepsy: global issues for the practicing neurologist. World Federation of Neurology seminars in clinical neurology*. New York, NY, Demos, 2005:95–105.
90. Jacoby A. Quality of Life: Age-Related Considerations. In: Engel J Jr, Pedley TA, eds. *Epilepsy - the Comprehensive CD-Rom*. Lippincott Williams & Wilkins, 1998.
91. Jacoby K, Jacoby A. Epilepsy and insurance in the UK: an exploratory survey of the experiences of people with epilepsy. *Epilepsy and Behavior*, 2005, 5:884–894.
92. Petersilia J. Invisible victims. *Human Rights*; 2000, 27:9–13.
93. Schultz U, Thorbecke R. Rehabilitationsprognose bei Epilepsiebeginn nach Eintritt ins Berufsleben. *Rehabilitation* 1985, 192-196.
94. Scharfenstein J, Thorbecke R. Rehabilitation Epilepsiekranker in einem Arbeit samts bezirk, Remschmidt C, ed. *Epilepsie* 1980, Stuttgart: Thieme, 1980; 22-28
95. De Boer HM. Epilepsy and society. *Epilepsia*, 1995, 36:8-11.
96. Parsonage M. Historical overview of the legislative aspects of epilepsy. In: Canger R, Loeber JN, Castellano F, eds. *Epilepsy and Society, realities and prospects*. Amsterdam, Excerpta Medica, 1988.
97. Epilepsy Foundation of America. *The legal rights of persons with epilepsy*. 6th edition, Landover, MD, 1992.
98. Epilepsy Foundation of America. *The Americans with Disabilities Act: a guide to provision affecting persons with seizure disorders*. Landover, MD, 1992
99. Mc Lin WM, de Boer HM. Public perceptions about epilepsy. *Epilepsia*, 1995, 36:957-959.
100. Global Campaign Against Epilepsy. *Epilepsy in the Western Pacific Region: a call to action*. Manila, World Health Organization Regional Office for the Western Pacific, 2004.
101. Arnston P et al. The perceived psychosocial consequences of having epilepsy. In: Whitman S, Herman B, eds. *Psychopathology in epilepsy: social dimensions*. Oxford, Oxford University Press, 1986:143–161.
102. Goffman E. *Stigma: notes on the management of spoiled identity*. Upper Saddle River, NJ, Prentice Hall, 1963.
103. Jones EE et al. *Social stigma: the psychology of marked relationships*. New York, NY, Freeman, 1984.
104. Temkin O. *The falling sickness*. Baltimore, MD, John Hopkins Press, 1971.
105. Conrad P. Epilepsy in Indonesia: notes from development. *Central Issues in Anthropology*, 1992, 10:94–102.
106. JilekAall L et al. Psychosocial study of epilepsy in Africa. *Social Science and Medicine*, 1997, 45:783–795.
107. Crocker J, Major B, Steele C. Social stigma. In: Gilbert DT, Fiske ST, Gardner L, eds. *The handbook of social psychology*, 4th ed. Boston, MA, McGraw Hill, 1998:504–553.
108. Schneider JW, Conrad P. *Having epilepsy: the experience and control of illness*. Philadelphia, PA, Temple University Press, 1983.

109. Kleinman A et al. The social course of epilepsy: chronic illness as social experience in interior China. *Social Science and Medicine*, 1995, 40:1319–1330.
110. Caveness WF, Gallup GH. A survey of public attitudes towards epilepsy in 1979 with an indication of trends over the past thirty years. *Epilepsia*, 1980, 21:509–518.
111. Baumann RJ, Wilson JF, Weise HJ. Kentuckians' attitudes toward children with epilepsy. *Epilepsia*, 1995, 36:1003–1008.
112. Scambler G. *Epilepsy*. London, Tavistock, 1989.
113. Jacoby A. Felt versus enacted stigma: a concept revisited. *Social Science and Medicine*, 1994, 38:269–274.
114. Hermann BP et al. Psychosocial predictors of psychopathology in epilepsy. *British Journal of Psychiatry*, 1990, 156:98–105.
115. Baker GA et al. Quality of life of people with epilepsy: a European study. *Epilepsia*, 1997, 38:353–362.
116. Baker GA et al. Quality of life of people with epilepsy in Iran, the Gulf and Near East. *Epilepsia*, 2005, 46:132–140.
117. Jalava M et al. Social adjustment and competence 35 years after onset of childhood epilepsy: a prospective controlled study. *Epilepsia*, 1997, 38:708–715.
118. *The World Health Report 2004 – Changing history*. Geneva, World Health Organization, 2004 (Annex Table 3, [http://www.who.int/whr/2004/annex/topic/en/annex\\_3\\_en.pdf](http://www.who.int/whr/2004/annex/topic/en/annex_3_en.pdf)).
119. Leonardi M, Ustun B. The global burden of epilepsy. *Epilepsia*, 2002, 43(Suppl.6):21–25.
120. Begley CE et al. The cost of epilepsy in the United States: an estimate from population-based and survey data. *Epilepsia*, 2000, 41:342–352.
121. Cockerell OC et al. The cost of epilepsy in the United Kingdom: an estimation based on the results of two population-based studies. *Epilepsy Research*, 1994, 18:249–260.
122. Thomas SV et al. Economic burden of epilepsy in India. *Epilepsia*, 2001, 42:1052–1060.
123. *Investing in health research and development. Report of the Ad Hoc Committee on Health Research relating to future intervention options*. Geneva, World Health Organization, 1996.
124. Chisholm D. Cost-effectiveness of first-line anti-epileptic drug treatments in the developing world: a population-level analysis. *Epilepsia*, 2005, 46:751–759.
125. Tan Torres T et al. *Making choices in health: WHO guide to cost-effectiveness analysis*. Geneva: World Health Organization, 2003.
126. Scott RA, Lhatoo SD, Sander JWAS. The treatment of epilepsy in developing countries: where do we go from here? *Bulletin of the World Health Organization*, 2001, 79:344–351.
127. ILAE/IBE/WHO Global Campaign Against Epilepsy. *Out of the shadows*. Geneva, World Health Organization ([http://www.who.int/mental\\_health/management/globalepilepsycampaign/en/](http://www.who.int/mental_health/management/globalepilepsycampaign/en/)).

Country, territory or area	Name
Afghanistan	<i>M. Sayed Azimi</i>
Albania	<i>Jera Kruja</i>
Algeria	<i>Abdelhafid Bouslimane</i>
Andorra	<i>Joan Obiols</i>
Angola	<i>Albino Cunene Coelho de Carvalho</i>
Argentina	<i>Roberto H. Caraballo</i>
Armenia	<i>Vahagn Darbinyan</i>
Australia	<i>Angela O'Connor</i>
Austria	<i>Christoph Baumgartner</i>
Azerbaijan	<i>Sharif S. Magalos</i>
Bahrain	<i>Kameshwar Prasad</i>
Bangladesh	<i>Md Rezaul Karim</i>
Barbados	<i>Sean Marquez</i>
Belarus	<i>Roman Evsegneev</i>
Belgium	<i>Paul A. J. M. Boon</i>
Bhutan	<i>P. Bhandari</i>
Botswana	<i>Patson N. Mazonde</i>
Brazil	<i>Carlos Eduardo Silvado</i>
Bulgaria	<i>Melania Radionova</i>
Burkina Faso	<i>Jean B. Kabore</i>
Burundi	<i>Léopold Nzisabira</i>
Cambodia	<i>Chea Lahoeurn</i>
Cameroon	<i>Louis Dongmo</i>
Canada	<i>Elout Starreveld</i>
Cape Verde	<i>Daniel Silves Ferreira</i>
Cayman Islands	<i>Bryan Jefferson Heap</i>
Central African Republic	<i>Joel Selguetia</i>
Chad	<i>Bolsane Egip</i>
Chile	<i>Tomas Mesa</i>
China	<i>Wenzhi Wang</i>
Colombia	<i>Jaime Faniño-Franky</i>
Congo	<i>Stéphane Ngampo</i>
Cook Islands	<i>Roro Daniel</i>
Costa Rica	<i>Franz Chaves Sell</i>
Côte d'Ivoire	<i>Joseph Délafosse</i>
Croatia	<i>Drago Škarpa</i>
Cuba	<i>Salvador González Pal</i>
Cyprus	<i>Andriane Flourentzou</i>
Czech Republic	<i>Milan Brázdil</i>
Democratic Republic of the Congo	<i>Mampunza Ma Miezi</i>
Denmark	<i>J. Alving</i>
Dominican Republic	<i>Diógenes Santos-Viloria Carlos Santoni William</i>

Country, territory or area	Name
Ecuador	<i>Arturo Carpio</i>
Egypt	<i>Mohamed Ghanem</i>
Equatorial Guinea	<i>Daisy Maria Bory Savigne</i>
Eritrea	<i>Fetsumberhan Gebrenegus</i>
Estonia	<i>Andre Õun</i>
Ethiopia	<i>Zenebe Gedlie Damtie</i>
Fiji	<i>J. Nasaroa</i>
Finland	<i>Reetta Kälviäinen</i>
France	<i>Pierre Genton</i>
French Polynesia	<i>Vincent Dupont</i>
Gabon	<i>Marie Laure Ntsame Ebang Gertrude Mouangue</i>
Gambia	<i>Ann Marie Mendy</i>
Georgia	<i>Natela Okujava</i>
Germany	<i>Christian E. Elger J. Bauer</i>
Ghana	<i>Paul Ayisu</i>
Greece	<i>Athanasios Covanis</i>
Grenada	<i>Robert Yearwood</i>
Guam	<i>Ramel A. Carlos</i>
Guatemala	<i>Henry B. Stokes</i>
Guinea	<i>Mariama Barry</i>
Guyana	<i>Bhiro Harry</i>
Honduras	<i>Claudia Amador</i>
Hungary	<i>Bèla Clemens</i>
Iceland	<i>Jon S. Gudnason</i>
India	<i>Satish Jain</i>
Indonesia	<i>Rusdi Maslim</i>
Iran, Islamic Republic of	<i>Kurosh Gharagozli</i>
Iraq	<i>Sarmed Al-Fahad</i>
Ireland	<i>Mike Glynn</i>
Israel	<i>Chani Baror</i>
Italy	<i>Paolo Tinuper</i>
Jamaica	<i>Amza Ali</i>
Japan	<i>Kazuichi Yagi</i>
Jordan	<i>AbdelKarim Al-Qudah</i>
Kazakhstan	<i>Aldungarova Roza</i>
Kenya	<i>David Musau Kiima Gachegu Gitonga</i>
Lao People's Democratic Republic	<i>Vikham Sengkignavong</i>
Latvia	<i>Egils Vitols</i>
Lebanon	<i>Naji Riachi</i>
Lesotho	<i>S. P. Shaikh</i>
Libyan Arab Jamahiriya	<i>Gheth M. Elworfally</i>
Lithuania	<i>Milda Endziniene</i>

Country, territory or area	Name
Madagascar	Adeline Raharivelo
Malawi	Theresa G. Mwale
Malaysia	Azmi Abdul Rashid
Malta	Janet Mifsud
Marshall Islands	Donald F. Capelle
Mauritania	Hamidou Traore
Mauritius	Gaya Geeaneswar Y. Noormamode
Mexico	Lilia Núñez Orozco
Micronesia, Federated States of	Imaculada J. Gonzaga Annette Zimmern
Mongolia	D. Baasanjav
Morocco	Abdeslam El Khamlichi
Mozambique	Paula Mogne
Myanmar	Nyan Tun
Namibia	Antonia Kangumine
Nepal	N. M. Shrestha
Netherlands	Gerrit-Jan De Haan
Netherlands Antilles – Curacao	Oscar Phillip Moen
New Zealand	Karen Covell
Nicaragua	Jorge Martínez Cerrato
Niger	Sadio Barry Hamid Assadeck
Nigeria	Mustapha A. Danesi
Niue	Athena de la Cruz Andrews
Norway	Karl O. Nakken
Pakistan	Hasan Aziz
Palau	Willie Tokon Stevenson Kuartei
Panama	Mario A. Larriátegui Arosemeroa
Papua New Guinea	David Mokela
Paraguay	Carlos Arbo Oze de Moruil
Peru	Patricia Campos Olazábal
Philippines	Leonor Cabral-Lim
Poland	Wendorff Janusz
Portugal	Francisco Pinto
Qatar	Ahmed Hamad
Republic of Korea	Lee Byung In
Republic of Moldova	Stanislav Groppa
Romania	Radu Rogozea
Russian Federation	Alla Guekht
Samoa	Satupaitea Viali
Sao Tome and Principe	Marta Maria Pósser
Saudi Arabia	D. R. McLean
Senegal	Amadou Gallo Diop

Country, territory or area	Name
Serbia and Montenegro	Nebojsa J. Jovic Marija Popovic
Singapore	Andrew Pan
Slovakia	Vladimir Donath
Slovenia	Dušan Butinar
Solomon Islands	Dick Boara
South Africa	Kathryn Pahl Bryan Kies
Spain	Antonio Gil-Nagel
Sri Lanka	Ranjanie Gamage
Suriname	Marian J. A. MacNack Eric Kafiluddin
Swaziland	R. Mdlangamandla
Sweden	Ingrid Olsson
Switzerland	Ernst N. Zweifel
Syrian Arab Republic	Ahmad Khalifa
Thailand	Surang Chiemchanya Bhakhaporn Bhirommai
The former Yugoslav Republic of Macedonia	Radoslav Naumovski
Timor-Leste	John Chinwuba Anaje E Somerville
Togo	Eric Kodjo Grunitzky
Tokelau	Fenuafala Faafoi
Tonga	Toakase Fakakuvietau
Trinidad and Tobago	Premchand Ratan Rohit Doon
Tunisia	Amel Mrabet
Turkey	S. Naz Yeni
Uganda	Augustine
Ukraine	Sergey Kcharchuk
United Kingdom (including Scotland)	Hilary Mounfield Josemir W. Sander Shelley Wagstaff
United Republic of Tanzania	Joseph Mbatia
United States of America	Susan Spencer M. Suzanne Berry
Uruguay	Alejandro Scaramelli
Uzbekistan	Shukhrat Khashimov
Vanuatu	Theto Moses
Venezuela, Bolivarian Republic of	Beatriz González Del Castillo
Viet Nam	Le Duc Hihn
Yemen	Abdulrahmen Muhammed Sallam Alkabati
Zambia	Anthony Mulenga Zimba
Zimbabwe	J. Mielke

